Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 3/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500761 | 0.95 | ITGB1 (0.43) | ITGB1ITGA5OPRL1AURKAMAPT | |
| SCHEMBL7080713 | 0.92 | ITGB1 (0.46) | ITGB1ITGA5OPRL1AURKAMAPT | |
| SCHEMBL6501443 | 0.89 | PIK3CA (0.40) | OPRL1F10GCGRKDRSCN2A | |
| SCHEMBL6499275 | 0.89 | MTTP (0.47) | ITGB1ITGA5OPRL1 | |
| SCHEMBL6490416 | 0.89 | CHRNB2 (0.43) | ITGB1ITGA5OPRL1TAS1R3TAS1R1 | |
| SCHEMBL6491904 | 0.88 | ITGB1 (0.43) | ITGB1ITGA5OPRL1GCGRAURKA | |
| SCHEMBL6490273 | 0.88 | GCGR (0.43) | F10GCGRAURKAMAPTSCN2A | |
| SCHEMBL6499999 | 0.87 | PPARG (0.49) | TAS1R3TAS1R1F10AURKATP53 | |
| SCHEMBL6793279 | 0.87 | POLB (0.47) | ITGB1ITGA5OPRL1AURKAMAPT | |
| Hydrochloric Acid SCHEMBL6792674 | 0.86 | POLB (0.47) | ITGB1ITGA5OPRL1AURKAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | ITGB1 642/4885ITGA5 2563/4885OPRL1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.